Lv5
908 积分 2021-11-15 加入
Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)
7小时前
求助中
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)
8小时前
待确认
Revolutionizing Anti-HER2 Therapies for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Current Advancements and Future Perspectives
9小时前
待确认
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
9小时前
待确认
Correction to: Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
1天前
待确认
CAR T cells induce a complete response in refractory Burkitt Lymphoma
2天前
已完结
CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma
2天前
已完结
Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review
2天前
已完结
CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease
2天前
已完结
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
5天前
已完结
皖公网安备34019202002308
